The FDA approved the use of ibrutinib (Imbruvica, Pharmacyclics/Janssen) in combination with rituximab (Rituxan, Genentech) for the treatment of adults with Waldenström macroglobulinemia (WM). Ibrutinib was approved for use as monotherapy for WM in January 2015.
“The approval of ibrutinib and rituximab has added a new option for many Waldenström’s patients,” said Steven P. Treon, MD, PhD, the director of the Dana-Farber Cancer Institute’s Bing Center